M-SRG

Fig1. Complete deletion of T, B and NK cells of M-SRG rats. Spleen and peripheral blood cells from SD and M-SRG rats were collected to analyze their compositions of T, B and NK cells by FACS.

Fig2. Subcutaneous xenograft tumor growth of HT29 cells in M-SRG rats.  Human colorectal adenocarcinoma cell line HT-29 (2x10⁷) were mixed with Matrigel and inoculated subcutaneously into M-SRG rats (n=6). (A)Tumor volume. (B) Body weight change.

Fig3. Subcutaneous xenograft tumor growth of PC-3 cells in M-SRG rats. Human prostatic adenocarcinoma cell line PC-3 (2x10⁷) were mixed with Matrigel and inoculated subcutaneously into M-SRG rats (n=6). (A)Tumor volume. (B) Body weight change.

Fig4. Subcutaneous xenograft tumor growth of LNCaP clone FGC cells in M-SRG rats. Human metastatic prostate carcinoma cell line LNCaP clone FGC (2x10⁷) were mixed with Matrigel and inoculated subcutaneously into M-SRG rats (n=6). (A)Tumor volume. (B) Body weight change. 

Fig5. Subcutaneous xenograft tumor growth of A2780 cells in M-SRG rats.  Human ovarian cancer cell line HT-29 (1x10⁷) were mixed with Matrigel and inoculated subcutaneously into M-SRG rats (n=6). (A)Tumor volume. (B) Body weight change. 

Fig6. Subcutaneous xenograft tumor growth of MV4-11 cells in M-SRG rats. Human monocytic leukemia cell line MV4-11 (1x10⁷) were mixed with Matrigel and inoculated subcutaneously into M-SRG rats (n=6). (A)Tumor volume. (B) Body weight change. 

Fig7. Subcutaneous xenograft tumor growth of OCI-AML-3 cells in M-SRG rats.  Human acute myeloid leukemia cell line OCI-AML-3 (1x10⁷) were mixed with Matrigel and inoculated subcutaneously into M-SRG rats (n=6). (A) Tumor volume. (B) Body weight change.

Fig8. Blood Routine Tests in M-SRG rats.  

Fig9. Blood biochemistry in M-SRG rats.